Key Takeaways
- FDA removed the REMS for CAR-T treatments and adjusted labeling to reduce the amount of time patients must remain in close proximity to the healthcare facility following infusion.
The US Food and Drug Administration’s elimination of the Risk Evaluation and Mitigation Strategies (REMS) for all currently approved BCMA-...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?